• Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

  • Jul 15 2022
  • Duración: 17 m
  • Podcast

Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study Por arte de portada

Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In this podcast, Dr. Javier Rodríguez-Carrio (1) talks to Dr. Tue Kragstrup (2) about the recent safety data on JAK inhibitors emerged after the ORAL Surveillance study. They discuss what is the current situation, the potential strategies to escape a ‘static’ situation, by managing uncertainty in the context of balancing risks, patient preferences and shared-decision process. Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002236

    (1) Javier Rodríguez-Carrio (University of Oviedo) (@javierrcarrio); (2) Tue Wenzel Kragstrup (University of Aarhus) (@KragstrupTW)
    Más Menos
Enfermedades Físicas Hygiene & Healthy Living
Más Menos

Lo que los oyentes dicen sobre Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles